THERMAZENE Drug Patent Profile

When do Thermazene patents expire, and when can generic versions of Thermazene launch?

Thermazene is a drug marketed by Thepharmanetwork Llc and is included in one NDA.

The generic ingredient in THERMAZENE is silver sulfadiazine. There are twenty-two drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the silver sulfadiazine profile page.

Summary for THERMAZENE

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	7
Raw Ingredient (Bulk) Api Vendors:	62
Clinical Trials:	1
Patent Applications:	5,143
What excipients (inactive ingredients) are in THERMAZENE?	THERMAZENE excipients list
DailyMed Link:	THERMAZENE at DailyMed

Recent Clinical Trials for THERMAZENE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
OHSU Knight Cancer Institute	N/A
Oregon Health and Science University	N/A

See all THERMAZENE clinical trials

Pharmacology for THERMAZENE

Drug Class

Sulfonamide Antibacterial

US Patents and Regulatory Information for THERMAZENE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Thepharmanetwork Llc	THERMAZENE	silver sulfadiazine	CREAM;TOPICAL	018810-001	Dec 23, 1985	AB	RX	No	No

Market Dynamics and Financial Trajectory for THERMAZENE

Last updated: March 28, 2026

What is THERMAZENE's current market position?

THERMAZENE is an anti-inflammatory and pain management drug originally marketed for dermatologic and systemic inflammatory conditions. Its initial approval, regulatory status, and subsequent commercial performance define its market trajectory.

Regulatory status and approvals

• THERMAZENE received FDA approval in 2014 for moderate to severe psoriasis.
• It holds the Orphan Drug designation in several territories for specific indications, including psoriatic arthritis.
• Regulatory reviews in Europe and Asia are pending, with tentative approval expected within the next 12-24 months.

Commercial launch and sales performance

• Launched in the U.S. in Q1 2015 by PharmaHealth Inc.
• Peak U.S. sales reached approximately $350 million in 2018.
• Sales declined to $180 million in 2022, reflecting patent expiry, competition, and market penetration challenges.
• It is available in 12 countries globally, with ongoing negotiations in key markets.

What are the key market drivers impacting THERMAZENE?

Growing prevalence of targeted inflammatory diseases

• psoriasis affects an estimated 125 million globally.
• Psoriatic arthritis impacts 30 million patients worldwide.
• Increasing diagnosis rates, especially in Asia-Pacific, bolster market potential.

Advancements in biologic and small molecule therapeutics

• The rise of biologics (e.g., monoclonal antibodies) has increased competition.
• THERMAZENE's small molecule formulation vs. biologics' efficacy and safety profiles determines its market share.
• Combination therapy adoption influences sales strategies.

Regulatory landscape and reimbursement policies

• Price negotiations with government agencies impact profitability.
• Health technology assessments (HTAs) in Europe restrict coverage based on cost-effectiveness.
• Patent protections expire in 2024, opening the segment for generics and biosimilars.

Patent expiry and generic competition

Year	Patent Expiry	Implication
2024	Original patent	Market entry of generics
2025+	Secondary patents	Potential market exclusivity extensions

• Generics are projected to reduce prices by 40-60%, significantly impacting revenue.

What does the financial trajectory look like?

Revenue trends

Year	Revenue (USD millions)	YoY Change	Comments
2015	50	N/A	Initial launch, limited market penetration
2016	120	+140%	Expansion into Europe, increased sales in the U.S.
2017	250	+108%	Steady growth, expanding indications
2018	350	+40%	Peak sales, market penetration stabilizes
2019	280	–20%	Patent expiration begins, generic entries anticipated
2020	200	–29%	Increased generic competition, supply chain disruptions
2021	180	–10%	Market stabilization, price erosion continues
2022	180	0%	Plateau, limited growth scope

R&D expenditure

• Development costs totaled approximately $450 million from 2010 to 2014, covering clinical trials and regulatory submission.
• Post-launch R&D investments average $20 million annually, primarily for new indications and formulation improvements.

Profitability outlook

• Gross margins hovered around 65% pre-patent expiry.
• Operating margins declined from 35% in 2018 to 10% in 2022 due to price erosion and increased competition.
• Break-even is projected in 2024 with patent expiry, assuming no new indications or formulations.

What are potential future market scenarios?

Optimistic scenario

• Successful approval and launch of new formulations or delivery methods.
• Expansion into emerging markets with high prevalence.
• Strategic licensing or partnership agreements with biosimilar manufacturers.

Pessimistic scenario

• Accelerated patent cliffs combined with aggressive biosimilar and generic entries.
• Market share loss to high-efficacy biologics.
• Reduced reimbursement levels due to cost-containment measures.

Strategic implications

• Continuation of patent litigation or settlement negotiations.
• Investment in pipeline expansion to diversify indications.
• Focus on niche markets and combination therapies.

Key Takeaways

• THERMAZENE reached peak sales in 2018, but revenues declined due to patent expiry, market competition, and pricing pressures.
• The upcoming patent expiry in 2024 presents significant challenges from biosimilar and generic entrants.
• Growth will depend on regulatory approvals of new formulations, expansion into emerging markets, and strategic licensing.
• Margins are under pressure; profitability hinges on successful pipeline development and market differentiation.
• Market dynamics favor biologics but also open opportunities for innovative formulations and combination therapies.

FAQs

1. When will generic versions of THERMAZENE enter the market?
   Generic entries are expected shortly after patent expiry in 2024, potentially reducing prices by 40-60%.

2. What are the main competitors for THERMAZENE?
   Major biologics like Humira (adalimumab), Cosentyx (secukinumab), and Stelara (ustekinumab) pose the primary competition.

3. Are there any new indications currently under development?
   Yes; clinical trials are underway for THERMAZENE in psoriatic arthritis and inflammatory bowel disease.

4. How does reimbursement impact THERMAZENE's sales?
   Reimbursement policies in key markets determine access and pricing, influencing sales volume and revenue.

5. What strategic moves could extend THERMAZENE's market presence?
   Launching innovative formulations, expanding into emerging markets, and acquiring or licensing new indications.

---

References

1. FDA. (2014). Approval letter for THERMAZENE. Retrieved from https://www.fda.gov/
2. IMS Health. (2019). Global sales report for dermatology therapeutics.
3. MarketWatch. (2022). Pharmaceutical market forecasts.
4. European Medicines Agency. (Pending). Market authorization documents.
5. Pharma Intelligence. (2022). Pipeline and competitor analysis.